Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

PURPOSE: Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both. The goal of this randomized phase II study was to evaluate two differe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Clarke, Jennifer L., Iwamoto, Fabio M., Sul, Joohee, Panageas, Katherine, Lassman, Andrew B., DeAngelis, Lisa M., Hormigo, Adília, Nolan, Craig P., Gavrilovic, Igor, Karimi, Sasan, Abrey, Lauren E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2009
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727290/
https://ncbi.nlm.nih.gov/pubmed/19506159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.7944
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller